Skip to main content
Addgene

pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2
(Plasmid #112004)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 112004 Standard format: Plasmid sent in bacteria as agar stab 1 $85
AAV9 112004-AAV9 Virus (100 µL at titer ≥ 1×10¹³ vg/mL) and Plasmid. $405

Backbone

  • Vector backbone
    pAAV
  • Backbone size w/o insert (bp) 4603
  • Total vector size (bp) 6772
  • Vector type
    Mammalian Expression, AAV

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    30°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    axon-GCaMP6s-P2A-mKate2
  • Alt name
    GAP43-GCaMP6s-P2A-mKate2
  • Species
    Synthetic
  • Insert Size (bp)
    2169
  • GenBank ID
    MH282428
  • Promoter hSynapsin1
  • Tag / Fusion Protein
    • GAP43 palmitoylation domain (N terminal on insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site BamHI (not destroyed)
  • 3′ cloning site HindIII (not destroyed)
  • 5′ sequencing primer GAAGGCGCGCTGACGTCACTCGCCG
  • 3′ sequencing primer CAAATTTTGTAATCCAGAGGTTGATT
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.

Information for AAV9 (Catalog # 112004-AAV9) ( Back to top)

Purpose

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 (#112004). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 plasmid DNA.

Synapsin-driven, axon-targeted GCaMP6s calcium sensor and bicistronic mKate2 expression. These AAV preparations are suitable purity for injection into animals.

Delivery

  • Volume 100 µL
  • Titer ≥ 1×10¹³ vg/mL
  • Pricing $375 USD for preparation of 100 µL virus + $30 USD for plasmid.
  • Storage Store at -80℃. Thaw just before use and keep on ice.
  • Shipment Viral particles are shipped frozen on dry ice. Plasmid DNA (≥ 200ng) will also be included in the shipment.

Viral Production & Use

  • Packaging Plasmids encode adenoviral helper sequences and AAV rep gene, AAV9 cap gene
  • Buffer PBS + 0.001% Poloxamer 188
  • Serotype AAV9
  • Purification Iodixanol gradient ultracentrifugation
  • Reporter Gene mKate2

Biosafety

Requestor is responsible for compliance with their institution's biosafety regulations. Lentivirus is generally considered BSL-2. AAV is generally considered BSL-1, but may require BSL-2 handling depending on the insert. Biosafety Guide

Terms and Licenses

Viral Quality Control

Quality Control:
  • Addgene ensures high quality viral vectors by optimizing and standardizing production protocols and performing rigorous quality control (QC) (see a list of our QC assays). The specific QC assays performed varies for each viral lot. To learn which specific QC assays were performed on your lot, please contact us.
  • Titer: the exact titer of your sample will be reported on the tube. The titer you see listed on this page is the guaranteed minimum titer. See how titers are measured.

Visit our viral production page for more information.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 was a gift from Lin Tian (Addgene plasmid # 112004 ; http://n2t.net/addgene:112004 ; RRID:Addgene_112004) For viral preps, please replace (Addgene plasmid # 112004) in the above sentence with: (Addgene viral prep # 112004-AAV9)
  • For your References section:

    In vivo measurement of afferent activity with axon-specific calcium imaging. Broussard GJ, Liang Y, Fridman M, Unger EK, Meng G, Xiao X, Ji N, Petreanu L, Tian L. Nat Neurosci. 2018 Sep;21(9):1272-1280. doi: 10.1038/s41593-018-0211-4. Epub 2018 Aug 20. 10.1038/s41593-018-0211-4 PubMed 30127424